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ABSTRACT 
Background&Aims: Innate immune system dysfunction is common in advanced 
cirrhosis, with a central role of the monocyte/macrophage system. Monocytes and 
macrophages express the scavenger receptor CD163 which is regulated by 
inflammatory mediators. Cleavage of the receptor leads to formation of soluble 
(s)CD163, that represents anti-inflammatory response. We aimed to study the clinical 
importance of sCD163 in cirrhosis.   
Methods: Sera of 378 patients were assayed for sCD163 by ELISA (193 outpatients 
and 185 patients with acute decompensation[AD]). A 5-year follow-up observational 
study was conducted to assess the possible association between sCD163 level and 
poor disease outcomes.  
Results: sCD163 level was associated with disease severity, but not with the presence 
of varices or prior variceal bleeding. In outpatients, sCD163 level did not predict the 
development of disease-specific complications or the long-term mortality. In patients 
with AD episode, sCD163 level was significantly higher compared to outpatients but 
only in the presence of bacterial infection[INF] (AD-INF:4586, AD-NON-INF:3792 and 
outpatients: 3538ng/mL, p<0.015 and p=0.001, respectively). sCD163 level gradually 
increased according to severity of infection. During bacterial infections, high sCD163 
level(>7000ng/mL) was associated with increased mortality rate (42% vs. 17%, 
p<0.001) and was identified as an independent predictor of 28-day mortality (HR:2.96, 
95%CI:1.27–6.95) in multivariate Cox-regression model comprising etiology, co-
morbidity, MELD score and leukocyte count as covariates.  
Conclusions: High sCD163 level is useful to identify patients with high-risk of death 
during an AD episode complicated by bacterial infection. This finding serves as an 
additional hint towards the significance of anti-inflammatory response during bacterial 
infection. 
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Key Points 
• The present 5-year follow-up cohort study comprehensively evaluated the 
significance of macrophage activation marker, soluble (s)CD163 in the prediction 
of poor disease outcomes in cirrhosis. 
• Previous findings that high serum level of sCD163 was an independent predictor 
of variceal bleeding and long-term mortality has not been confirmed. sCD163 
level did not predict development of other long-term complications (ascites 
formation, hepatic encephalopathy, and bacterial infections).  
• During bacterial infection, a high sCD163 level was a risk factor of short-term 
mortality independently from disease severity and the extent of pro-inflammatory 
response. 
• These results highlight the deleterious effect of the excessive anti-inflammatory 
response during bacterial infection.  
 
Introduction 
Leading causes of hospitalization in patients with cirrhosis include hepatic 
encephalopathy, upper gastrointestinal bleeding, bacterial infections and rapid 
accumulation of ascites; collectively referred to as acute decompensation (AD) [1]. 
During AD episodes a proportion of patients newly develop liver and/or extrahepatic 
organ failure(s), a distinct clinical entity defined as acute-on-chronic liver failure (ACLF) 
[1]. ACLF has recently gained great interest for several reasons. The syndrome is 
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associated with high short-term mortality, but precipitating factors and the exact 
pathogenetic processes have not yet been completely identified [2]. Bacterial infections 
clearly have an important role [3]. Various clinical factors have been established as 
predictors of short-term mortality in patients with bacterial infection [4]. Biomarkers 
identifying relevant pathophysiological pathways in patients with infection potentially 
may add value to understanding and managing this condition [5]. 
 Monocytes and macrophages are important cellular components of the innate 
immune system. Resident macrophages of the liver, Kupffer cells, have a central role in 
the orchestration of pro- and anti-inflammatory processes and have been studied 
extensively in chronic liver diseases [6]. During inflammation the haemoglobin-
haptoglobin scavenger receptor, CD163 is cleaved from the surface of macrophages. 
This soluble form (sCD163) is thereafter detectable in the systemic circulation and 
regarded as a marker of macrophage activation [7,8]. Binding and internalization of the 
haemoglobin-haptoglobin complex is a well described function of this receptor, but 
several other functions have also been attributed to CD163 [8]. CD163 is expressed on 
M2-type (pro-resolution, anti-inflammatory) liver macrophages in the presence of local 
microenvironmental anti-inflammatory signals such as interleukin (IL)-10 [9,10]. 
Accordingly, high serum level of sCD163 has been considered as a representative 
marker of the anti-inflammatory response in a number of clinical studies [11–14]  
Recently, monocytes and macrophages of anti-inflammatory properties were highlighted 
in the pathogenesis of AD and development of organ failure in cirrhosis [15,16].  
Increased serum sCD163 level were found in non-cirrhotic patients during 
bacterial infection and even higher levels in sepsis. An association between increased 
sCD163 level and reduced survival has also been reported [11,12,17,18]. In cirrhosis, 
increased sCD163 level was reported in patients with significant portal hypertension or 
advanced disease stage [19–21]. It was also demonstrated that the sources of sCD163 
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were the macrophages of the liver [20]. Moreover, in a study of Waidmann et al. [22], 
sCD163 level was found to be a prognostic marker of overall survival and the 
development of variceal bleeding. Development of other long-term complications (i.e. 
hepatic encephalopathy, ascites and bacterial infections) of cirrhosis in relation to 
sCD163 level however, has not been yet evaluated. In addition no data are available 
regarding the significance of macrophage activation represented by sCD163 serum 
level during bacterial infection and/or other AD episodes of cirrhosis. 
The aim of the present study was to investigate the clinical importance of 
sCD163 in a large referral patient cohort with cirrhosis. The primary aim was to assess  
the association between serum sCD163 level and the disease specific characteristics 
(disease severity, portal hypertension or presence and type of the acute 
decompensation event). Secondary aim was to evaluate whether sCD163 level is able 
to predict poor disease outcomes in cirrhosis. (1) In stable outpatients we evaluated the 
advent of decompensation events (ascites formation, hepatic encephalopathy, variceal 
bleeding, and/or bacterial infections) and long-term mortality. (2) In patients with acute 
decompensation we evaluated short-term mortality with careful distinction of bacterial 
infections.   
 
Patients and methods 
 
Patient population 
We performed a cohort study among adult patients with established diagnosis of 
cirrhosis of different etiologies in a tertiary care referral center of Hungary (Division of 
Gastroenterology Department of Internal Medicine, Clinical Center, University of 
Debrecen). This cohort was reported in previous serological studies of our group 
[23,24]. Between May 1, 2006 and December 31, 2010, patients were included 
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consecutively from the outpatient clinic during regular or extraordinary follow-up visits 
and also from the inpatient ward due to hospitalization with an AD episode. The 
exclusion criteria were (1) if the patient or his/her legal surrogate declined to participate 
in the study and did not sign the informed consent or (2) if the patient was sent just for 
specialist consultation, and followed-up regularly elsewhere. For present study serum 
samples of 378 patients (193 outpatients and 185 hospitalized subjects due to an AD 
episode) were available.  
Clinical characteristics of the patients at inclusion are presented in Table 1. 
Diagnosis of cirrhosis was based on clinical, biochemical, imaging and when available, 
histological data. Blood samples, routine laboratory data and detailed clinical phenotype 
were captured at inclusion. Clinical data were determined by in-depth review of the 
patients’ medical records using a structured interview. Medical records that documented 
age at diagnosis, etiology, presence of esophageal varices, history of previous AD 
episode(s), presence of hepatocellular carcinoma, extrahepatic co-morbidities 
(myocardial infarction, congestive heart failure, peripheral arterial disease, 
cerebrovascular disease, chronic pulmonary disease, chronic renal failure, diabetes 
mellitus, extra-hepatic malignant disease) and cirrhosis-related medication were 
retrospectively analyzed for the period prior to the observational follow-up study. 
Indications for non-selective beta-blockers either in primary or secondary prophylaxis of 
variceal bleeding were considered on the recommendation of current guidelines [25]. 
Indications for proton pump inhibitors were gastroesophageal reflux disease, erosive 
gastritis, peptic ulcer disease or treatment for Helicobater pylori infection [26]. At 
enrolment, disease severity assessed by liver-oriented scores (Child-Pugh and MELD) 
were determined. If present, the type of the AD episode was established. Acute 
decompensation was defined by one or any combination of the following events: 
development of large ascites, hepatic encephalopathy, gastrointestinal hemorrhage and 
8 
 
bacterial infection. Development of large ascites was defined by grade II/III ascites, 
according to the International Club of Ascites [27], patients with refractory ascites were 
not included. Acute hepatic encephalopathy was defined by acute worsening of mental 
status in a previously conscious patient, without the evidence of acute neurological 
disease [28]. Acute gastrointestinal bleeding was diagnosed by esophago-gastro-
duodenoscopy, and was attributed to acute variceal bleeding according to conventional 
criteria [29]. Presence of systemic bacterial infection was carefully established by 
compatible clinical symptoms, laboratory data (leucocyte count, high-sensitivity C-
reactive protein [CRP] and procalcitonin [PCT], results of urine analysis (sediment) and 
imaging findings (abdominal ultrasound and chest X-ray) and if ascites was present the 
result of diagnostic tap (neutrophil count and ascites culture) was considered in all 
patients with AD episode. Based on the results of this procedure, cultures from specific 
sites (sputum, urine, wound discharge, etc.) were obtained according to location of 
infection, though blood cultures were obtained in sepsis, or if the location of the 
infection could not be clearly identified. Regarding laboratory results, elevated leucocyte 
count (absolute: >10.8 G/L or relative [in patients with leukopenia]: double of count at 
former visits) with an elevated neutrophil rate (>76%) and increased serum levels of 
CRP (>10.0 mg/L) and/or PCT (>0.15 µg/L) [23] were considered to support the 
diagnosis of infection. Based on specific clinical symptoms and findings the following 
infections were diagnosed. (1) Spontaneous bacterial peritonitis (SBP): neutrophil cell 
count >250/mm3 and/or positive culture of ascitic fluid, in the absence of intra-
abdominal source of infection. (2) Urinary tract infection: presence of dysuria, pyuria 
(leucocyte >10/mm3) and positive urine culture. (3) Pneumonia: presence of cough and 
expectoration, positive chest X-ray, positive sputum culture. (4) Miscellaneous: skin and 
soft tissue, biliary tract, orocavital, intestinal tract infection, osteomyelitis, endocarditis. 
(5) Bacterial infection with unknown origin: positive blood culture in the absence of site-
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specific infection.  
Further characterization of bacterial infections was done on the basis of 
conventional criteria [30–33]. Additionally, during AD events presence of ACLF and its 
grade was also assessed, although only retrospectively after the new definition of ACLF 
became available in September, 2013 [1]. 
The control group consisted of 150 age and gender matched healthy blood 
donors (male/female: 72/78, age: 51.5±16.9 years).  
 
Phenotypical characterization of patients during follow-up 
Patients were enrolled into an observational follow-up study, where the attending 
gastroenterologist registered laboratory data, imaging and endoscopic findings, disease 
severity, medical treatment, date and type of disease specific complications during 
regular and extraordinary outpatient follow-up visits and inpatient stays. In Hungary, a 
regular outpatient follow-up visit is usually scheduled for every 3 months at a 
specialized gastroenterology center for patients with decompensated cirrhosis (a follow-
up between 1-3 months may be scheduled if dictated by disease severity or presence of 
certain disease specific complications) and for up to 6 months for patients with cirrhosis 
but without prior episode of AD. The follow-up period lasted 5 years, or death/loss of 
follow-up. The median follow up was 661 days (IQR: 104-1563). 
Collected data were transferred and stored in a database. At the end of the study 
period, December 31, 2013, all clinical data were extracted for further analysis. 
Development of complications, (i.e. occurrence of ascites formation, variceal bleeding, 
hepatic encephalopathy, clinically significant bacterial infection or death were defined as 
adverse outcomes.  
 
Serological analysis 
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Blood samples were obtained at enrolment from each patient and were frozen at -70°C 
until testing, 2013 May. Very high stability of the molecule over time and different 
conditions were reported previously. sCD163 was resistant to repeated freezing and 
thawing. [8,34]. Serum level of sCD163 were determined by a solid-phase enzyme-
linked immunoassay, according to the manufacturer’s instructions (IQProducts, 
Groningen, Netherlands), in a blinded fashion. Samples were measured in duplicates 
on the same plate, and the mean values was used. Between runs, coefficients of 
variation (CV) were 8%. The limit of detection was 0.23 ng/mL. sCD14 evaluation was 
performed previously [23], using ELISA (Quantikine, R&D Systems, Minneapolis, MN). 
Serological assays were performed at the Department of Laboratory Medicine in a 
blinded fashion by a qualified analyst (E.T.) without prior knowledge of the patient’s 
clinical information. 
 
Ethical considerations 
The study protocol was approved by Regional and Institutional Research Ethics 
Committee of University of Debrecen and the National Scientific and Research Ethics 
Committee. (DEOEC RKEB/IKEB 5306-9/2011, 3885/2012/EKU [60/PI/2012]). Each 
patient or legal surrogate was informed of the nature of the study and signed an 
informed consent form. 
 
Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous variables 
were summarized as means (standard deviation [SD]) or as medians (interquartile 
range [IQR, lowest 25%- highest 25%]) according to their homogeneity. Categorical 
variables were compared with Fisher’s exact test or χ
2 test with Yates correction, as 
appropriate. Continuous variables were compared with Mann-Whitney U test or Kruskal-
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Wallis H test with Dunn’s multiple comparison post hoc analysis. Paired samples were 
analyzed by Wilcoxon signed rank test. The Spearman’s nonparametric rank correlation 
test was used to determine correlations. Ability of different variables to discriminate 
between survivors and non-survivors in patients with bacterial infection were assessed 
by receiver operating characteristics curve (ROC) analysis plotting sensitivity vs. 1-
specificity. Area under the curve (AUROC) and corresponding 95 % confidence 
intervals (CI) were calculated. Youden index was chosen, calculated as the maximum 
(sensitivity+specificity-1) value, to estimate the best discriminate threshold. Sensitivities, 
specificities, positive predictive values (PPV) and negative predictive values (NPV) were 
calculated at the best discriminate threshold of the variables. ROC curves were 
compared with the method of DeLong et al. in Medcalc. Kaplan–Meier survival curves 
were plotted to estimate the cumulative probability of 28-day survival during AD episode 
in patients with or without bacterial infections. Differences in observed probabilities were 
assessed by the log-rank test. The association between categorical clinical variables or 
sCD163 serum level and adverse disease outcomes during follow-up were assessed by 
univariate Cox-regression analysis. Multivariate analyses were performed with 
backward elimination procedure and likelihood ratio test to identify independent 
predictors. Associations are given as hazard ratio [HR] with 95% confidence intervals 
[CI]. We aimed to help the interpretation of the results of the multivariate Cox regression 
table in patients with bacterial infection, in which HRs of categorical and continuous 
variables are presented. For this data visualization purpose we applied the method 
developed by Liu et al. [35]. We used PROC PHREG in SAS (version 9.1.3, SAS 
Institute, Carry, NC), with BASELINE statement to output estimated survival function at 
day 28 for each combination of the explanatory variable values present in the dataset 
and selected for visualisation, and then was plotted against the selected continuous 
variable (leukocyte count). For statistical analysis and graphical presentation the SPSS 
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22.0 [SPSS, Chicago, IL], and GraphPad Prism 6 [San Diego, CA] programs were used. 
A 2-sided probability value of <0.05 was considered to be statistically significant. 
 
Results 
Serum values of sCD163 ranged from 279 to 28818 ng/mL in the total patient 
population and was significantly higher compared to healthy subjects (median [IQR], 
3852 ng/mL [2265-6542] vs. 1104 ng/mL [863-1438], p<0.001). sCD163 level increased 
gradually according to disease severity, as rated by the Child-Pugh stage (A: median 
[IQR]: 2984 [1839-4999], B: 3838 [2392-6432] and C: 5917 [3235-8266] ng/ml, p<0.001 
for all). Further evaluating this association in outpatients and patients with AD 
separately yielded the same result (data not shown).  
Significant correlation was found between sCD163 level and laboratory markers 
of inflammation, impaired renal and liver function and accordingly with liver-oriented 
scores (Child-Pugh and MELD), and also with markers of portal hypertension. Non-
parametric correlations are summarized in Supplementary Table 1.  
 
sCD163 level in outpatients 
In a total of 193 outpatient subjects, sCD163 level was not associated with the presence 
of portal hypertension characterized by the presence of ascites (Fig. 1A), prior episodes 
of variceal bleeding or presence of esophageal varices (Fig. 1B). 
We then analyzed the association between sCD163 level and poor disease 
outcomes (advent of AD events and liver-related death).  
Seventy-seven patients (39.9%) developed some type of AD episode. Forty-four 
(57%) of them had more than one episode during the long-term follow-up (median 
[IQR], 939 [323-1825] days). The distribution of different AD episodes is shown in Table 
1. The median time to first AD episodes was 511 days [109-840]. Serum sCD163 level 
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did not predict the development of ascites (HR: 0.90, 95%CI: 0.46-1.75) or the advent of 
episodes of variceal bleeding (HR: 0.92, 95%CI: 0.46-1.82), hepatic encephalopathy 
(HR: 1.47, 95%CI: 0.86-2.51) and clinically significant bacterial infection (HR: 1.32, 
95%CI: 0.88-1.96) in univariate Cox models. The sensitivity analysis performed in 
patients with no previous decompensation event, after excluding patients with a prior 
AD episode (n=88) yielded the same result regarding the development of disease 
specific complications (data not shown).  
Fifty patients (25.9%) died of liver-related complications. The median time to 
death was 542 days (IQR: 178-756). Univariate survival analysis, however, 
demonstrated a significantly worse survival in patients with increased sCD163 level 
(HR: 1.72, 95%CI: 1.15-2.57, p=0.008) (Table 2A). Further evaluation of this 
association in a multivariate Cox-regression model comprising age, gender and clinical 
variables showed only clinical factors (advanced disease according to Child–Pugh 
stage and presence of co-morbidity, p<0.001 and p<0.01, respectively), but not sCD163 
level (HR: 1.38, 95%CI: 0.91-2.08, p=0.127) were independent predictors of long-term 
survival in outpatients (Table 2B). 
 
sCD163 level in patients with acute decompensation episode 
In a total of 185 patients with acute decompensation episode, sCD163 level was 
significantly higher in patients with AD episode compared to outpatients, but only in the 
presence of bacterial infection (Fig. 2A). We were also able to confirm this association 
intra-individually. In a subgroup of stable outpatients (n=33), during a subsequent AD 
episode with an ongoing bacterial infection, sCD163 level showed a significant increase 
(median [IQR], 3210 [2024-7364] vs. 5119 ng/mL [2940-9761], p=0.038). Median time 
between sample procurements was 220 days [48–999]. As a control, outpatients (n=59) 
having a subsequent sample from a later outpatient visit with comparable time-lag 
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(median, IQR: 261 [113-1046] days) were also assessed, however, sCD163 level did 
not show significant change (3200 [2304-5517] vs. 3857 ng/ml [2477-5669], p=0.72).  
Accordingly, we further evaluated the 99 infectious cases. Distribution of the 
different clinically significant infections was the following: 22,2% spontaneous bacterial 
peritonitis, 15.2% pneumonia, 22.2% urinary tract infection, 7.1% miscellaneous, 15.2% 
unidentified and 18.2% of the cases were multifocal. Bacteria were Gram-negative in 
52.6% and Gram-positive in 47.4% of culture-positive cases. sCD163 level was not 
different according to either the location or Gram specificity of the infection. Moreover, 
patients with multifocal infections had similar sCD163 level to those with unifocal ones 
(data not shown). Severity of organ failure was significantly higher in infectious AD 
cases as compared to non-infectious AD cases based on both the results of the MELD 
score (median [IQR]: 17 [14-22] vs. 14 [11-20], p=0.005) and the proportion of patients 
with ACLF (29.3% vs.15.1%, p=0.022). Nonetheless, sCD163 level was associated with 
the severity of the infection. sCD163 levels were significantly higher in patients 
complicated with organ dysfunction(s), namely ACLF, compared to those without 
(median [IQR], 7233 ng/mL [3864-11643] vs. 3864 ng/mL [2700-7031], p=0.003). 
 
sCD163 associated with short-term mortality during infectious episodes 
Twenty-five patients with bacterial infection (25%) died during the first 28 days of 
follow-up. sCD163 level at admission were significantly higher in non-survivors than 
survivors (median [IQR], 7233 ng/mL [3594-10337] vs. 4045 ng/mL [2700-7355], 
p=0.029). MELD score (24 [20-33] vs. 16 [12-20]), CRP level (51 mg/l [33-93] vs. 26 
mg/l [13-47]) and also leukocyte count (12.1 G/l [6.3-15.4] vs. 7.2 G/l [5.1-10.1]) were 
significantly different between the two groups (p<0.001, p=0.001, p=0.014, 
respectively).  
Prognostic accuracy of sCD163 level for predicting short-term mortality in 
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patients with bacterial infection was established by ROC analysis and compared to 
MELD score and CRP. sCD163 was similar predictor of short-term mortality compared 
to CRP (AUROC [95% CI]: 0.65 [0.54-0.74]) vs. 0.73 [0.63-0.81], p=0.31) but inferior to 
MELD score (0.83 [0.74-0.90], p<0.01).  
The best discriminate threshold for sCD163 level estimated by the Youden-index 
was 7000 ng/mL, with sensitivity, specificity, PPV, NPV of 56.5%, 72.9%, 41.2%, and 
83.1%, respectively. The optimum threshold for CRP and MELD was >30 mg/l and a 
score of >21, respectively. Their performance belonging to the cut-off values are shown 
in Supplementary Table 2.  
In the univariate Cox-regression analysis, patients with high sCD163 level 
(>7000 ng/mL) and bacterial infection had significantly higher risk of short-term mortality 
when compared to those with low sCD163 level (HR: 3.04, [95%CI: 1.38-6.71], 
p=0.006). Using this derived cut-off in patients without bacterial infection, however, 
elevated level of sCD163 was not associated with short-term mortality. Kaplan-Meier 
survival curves for subgroups of AD patients with or without bacterial infection is 
demonstrated in Figure 3. Of the clinical factors, disease etiology and presence of co-
morbidities but not the patients’ age, gender or the presence of ascites and prior AD 
episode within 6 months were significantly associated with short-term mortality. 
Furthermore, disease severity depicted by MELD score and increased level of markers 
related to pro-inflammatory response (CRP and leukocyte count) were also significantly 
associated with short-term mortality in patients with bacterial infections (Table 3). 
Multivariate Cox regression analysis indicated that sCD163 level did remain an 
independent predictor of short-term mortality during bacterial infection (HR: 2.96, 
[95%CI: 1.27-6.95], p=0.012), next to presence of co-morbidities, disease etiology, high 
MELD score (> 21) and leukocyte count, whereas CRP lost its significance (Table 3). 
To visualize the impact of sCD163 level on short-term mortality, we plotted the 
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estimated event rates according to leukocyte count as a continuous variable in the four 
different subgroups of patients (Fig. 4). In the case of a high level of sCD163, the 28-
day mortality rate is increased both in groups with high or low MELD score at any given 
value of leukocyte count.  
 
Discussion 
The soluble form of CD163 scavenger receptor has long been known as a surrogate 
parameter of macrophage activation in various diseases [8], and has a good correlation 
with other soluble macrophage activation markers, such as soluble urokinase 
plasminogen activator receptor (suPAR), soluble mannose receptor [12,36,37], but does 
not correlate with sCD14 [38], that is also shed from macrophages. In the present study 
however sCD163 had a significant but inverse correlation with sCD14.  
 Recently sCD163 has emerged as a promising novel marker in cirrhosis [22]. 
Enhanced formation of sCD163 is a well-known characteristic of cirrhosis and is 
consistently associated with advanced disease stage in the few currently available 
clinical studies [19,20]. Nonetheless, changes in the serum level of sCD163 during 
various types of AD episodes are less known and there are still many questions 
regarding its predictive role in the development of disease specific complications during 
the disease course. This is the rationale for the present study in which we 
comprehensively assessed the utility of serum sCD163 level in a large prospective 
cirrhotic patient cohort with a careful assessment of acute deterioration. 
 First, we evaluated the association between sCD163 level and the disease 
specific characteristics of the cirrhotic patients. We were able to confirm previous 
findings that in cirrhosis, sCD163 level does increase up to the three-fold higher than 
the value observed in control subjects and displays a gradual increase according to 
disease severity [19,20]. Median sCD163 values in our cohort corresponded to those 
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reported previously.  
Association of sCD163 level to clinically significant portal hypertension was 
extensively assessed in cirrhosis previously, but yielded somewhat conflicting results. 
sCD163 level was positively correlated to portal hypertension assessed by invasive 
hemodynamic measurement [20]. Interestingly, alleviation of portal pressure by TIPS 
insertion was not followed by a significant drop in sCD163 level. A later study by the 
same Danish group [19], revealed that significant correlation between sCD163 level and 
portal hypertension was only present in early, but not in advanced disease stages. 
Contrary to invasive hemodynamic studies, sCD163 level did not differ according to 
presence or absence of esophageal varices or in acute bleeding [22]. Correspondingly, 
we also found that the sCD163 level was not associated with the presence of varices, 
prior or recent variceal bleeding episodes.  
In the present study, sCD163 level was neither associated with poor disease 
outcomes in outpatients, nor with the development of disease-specific complications or 
the overall survival during follow-up. In cirrhosis, one single prospective study [22] 
assessed the predictive value of sCD163 level during the disease course, and reported 
that increased sCD163 level was an independent predictor of variceal bleeding and 
long-term mortality. That large consecutive single center cohort (n=244) comprised both 
outpatients and subjects hospitalized due to acute complications of cirrhosis. Thirty 
percent of their patients had a concomitant bacterial infection. Regarding clinical 
characteristics, a comparable patient population was included in our study, but a 
different approach was applied for the evaluation. Outpatients and patients with ongoing 
AD episodes were not included in one single study group, as in the research of 
Waidmann et al., but were considered as two distinct patient populations for several 
reasons. On the one hand, infectious episodes represent particularly important causes 
of progression of liver failure and development of liver-related complications in patients 
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with cirrhosis [5]. Moreover, regardless of the severity of hepatic insufficiency, 
development of bacterial infection significantly increases mortality rate. In-hospital 
mortality of cirrhotic patients with infection is more than twice that of patients without 
infection [39]. On the other hand, sCD163 level increases during bacterial infections 
both in non-cirrhotic [11,12] and cirrhotic [22] patient populations. Waidmann et al. 
demonstrated significantly higher level of sCD163 in cirrhotic patients (n=79) with 
bacterial infections. However, in their paper it was also stated that the sCD163 level 
remained constant for several weeks and was not substantially affected by acute 
bacterial infections during sequential examination of a small group of patients (n=7). As 
for our cohort, we have shown that sCD163 is increased in patients with bacterial 
infection. We were able to confirm this association intra-individual as well as in a larger 
group of patients (n=33). Furthermore we have also shown that the presence of 
bacterial infection is the only factor that significantly influences the level of sCD163 
during AD episodes. Interestingly, we found that the more severe the infection – defined 
by the presence of organ failure(s) – the higher the level of sCD163. This finding is in 
agreement with the results of the early study of Møller et al. [12], in which sCD163 level 
was significantly higher during pneumococcal infection in cases complicated by organ 
failure in non-cirrhotic patients.  
 Here, we have shown for the first time [40], that in cirrhosis the 28-day mortality 
was associated with increased sCD163 level (>7000 ng/mL) during bacterial infection. 
Almost half of the patients with high level of sCD163 died compared to only 16% of 
patients with low level of sCD163. Short-term mortality risk associated with high 
sCD163 level (HR: 2.96) was very similar to the risk (HR: 3.05) associated with high 
suPAR level, another macrophage activation marker, reported in the study of 
Zimmermann et al. [41]. In our study sCD163 was an independent risk factor regardless 
of the disease severity and the extent of the pro-inflammatory response, represented by 
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MELD score, CRP and leukocyte count, respectively. This finding is consistent with the 
observations that excessive anti-inflammatory response, represented by interleukin-10, 
interleukin-6 [42] or soluble tumor necrosis factor-α receptor (sTNFR) [43] and 
decreased monocyte HLA-DR expression [15] has a significant negative impact on 
survival in cirrhosis, as recently reviewed by Albillos et al. [44]. Interestingly various 
markers of the anti-inflammatory response had similar short-term mortality risk than 
sCD163 in our study.  
The deleterious effect of the exaggerated anti-inflammatory response is 
attributed to the impaired response to microbial challenge. A recent study from 
Bernsmeier et al. further highlighted the role of CD163high monocytes/macrophages in 
this process. They demonstrated that the impaired response to microbial challenge 
could be restored by modulating anti-inflammatory (CD163high-MERTK positive) 
monocytes in vitro [16]. 
During bacterial infection, accurate and early selection of the most vulnerable 
patients requiring intensive care and monitoring is of importance in clinical practice [5]. 
From a pathophysiological point of view including a representative biomarker of the 
altered anti-inflammatory pathway into a predictive model makes sense. sCD163 might 
be a promising candidate for this purpose based on our findings. The present study, 
however, had an exploratory purpose. The relatively low sample size of patients with 
bacterial infection (n=99), and the single centre design did not allow us to satisfy the 
above mentioned, but so far unmet need. Recently predictive models of cirrhosis and 
short-term survival were developed in multicenter cohorts with much larger patient 
populations [4,45]. Our single-point measurement approach did not allow for evaluating 
the potential importance of sCD163 kinetics, which is another limitation of our study. 
To conclude, the findings of our referral cohort study of patients with cirrhosis 
indicate that serum sCD163 levels are not useful in outpatients for predicting 
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complications or death; however, it may be a useful marker for the short-term 
stratification of patients with bacterial infection. In this patient population, high sCD163 
level is a risk factor for the short-term mortality independently from both the disease 
severity and the extent of the pro-inflammatory response. These results further highlight 
the deleterious effect of the excessive anti-inflammatory response during bacterial 
infection. 
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Table 1. Epidemiologic, clinical and laboratory characteristics of patients with cirrhosis 
 
 
 
All  
patients 
n=378 
Stable  
outpatients 
n=193 
Acute  
decompensation 
n=185 
Gender (male/female) 205/173 93/100 112/73 
Age (years)a 56 (50-64) 55 (49-63) 58 (51-65) 
Etiology, n (%) 
 
Alcohol 
Viral 
Other 
244(64.5) 
111 (29.4) 
23 (6.1) 
99 (51.3) 
78 (40.4) 
16 (8.3) 
146 (78.9) 
30 (16.2) 
9 (4.9) 
Child-Pugh 
stage, 
n (%) 
A 
B 
C 
135 (35.7) 
147 (38.9) 
96 (25.4) 
113 (58.6) 
66 (34.2) 
14 (7.2) 
22 (11.9) 
81 (43.8) 
82 (44.3) 
MELD scorea 14 (10-18) 11 (8-14) 16 (12-21) 
Serum bilirubin (µmol/L)a 33 (18-70) 26.2 (15-43) 52.5 (26-108) 
Serum albumin (g/L)a 32 (27-39) 38 (32-43) 28 (24-32) 
INRa 1.3 (1.1-1.5) 1.2 (1.1-1.4) 1.4 (1.2-1.7) 
Ascites present, n (%) 192 (50.8) 61 (31.6) 139 (75.1) 
Hepatocellular carcinoma, n (%) 41 (10.8) 22 (11.4) 19 (10.3) 
Co-morbidities present, n (%) 191 (50.5) 91 (47.5) 100 (54.1) 
Co-medication present, n (%) 
NSSB use 
PPI use  
82 (42.5) 
65 (33.7)  
Follow up time (days)a 661 
(104-1563) 
939 
(323-1825) 
315 
(25-1292) 
Patients with ascites formationb 
 
22 (16.7) 
 
26 
 
complications 
during follow-
up, n (%) 
variceal bleeding 
 
18 (9.3) 
 HE 
 
29 (15.0) 
 bacterial infection 
 
59 (30.6) 
 
 
a median, IQR (lowest 25%- highest 25%); b in patients without ascites, INR: 
international normalized ratio; HE: hepatic encephalopathy, NSSBs: non-selective beta-
blockers, PPIs: proton-pump inhibitors 
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Table 2. Univariate (A) and multivariate (B) Cox-regression analysis of clinical 
parameters and sCD163 level associated with overall survival in stable outpatients 
(n=193)  
A 
 
Hazard Ratio 95% CI p value 
Age >65 years 1.80 0.96-3.39 0.069 
Gender (male) 0.66 0.37-1.15 0.141 
Etiology  1.62 0.90-2.94 0.110 
Co-morbidities 2.13 1.20-3.77 0.010 
NSSB co-medication 1.45 0.83-2.53 0.188 
PPI co-medication 1.84 1.05-3.24 0.034 
Child A Reference 
Child B 3.56 1.93-6.57 < 0.001 
Child C 6.91 2.86-16.72 < 0.001 
Ln(serum sCD163 level) 1.72 1.15-2.57 0.008 
 
B 
 
Hazard Ratio 95% CI p value 
Age >65 years 1.70 0.85-3.42 0.135 
Gender (male) 0.63 0.35-1.11 0.111 
Co-morbidities 2.22 1.24-3.97 0.007 
PPI co-medication 1.50 0.84-2.67 0.167 
Child A Reference 
Child B 3.49 1.89-6.47 <0.001 
Child C 7.80 3.20-19.07 <0.001 
Ln(serum sCD163 level) 1.38 0.91-2.08 0.127 
 
CI: confidence interval, NSSB: non-selective beta-blocker, PPI: proton-pump inhibitor 
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Table 3. Univariate and multivariate Cox-regression analysis for the association of risk 
factors of short-term mortality in patients with infection (n=99) 
 
  Univariate Model 
 
Multivariate Model 
(Backward LR) 
Variables 
 
28-day mortality 
% (n) 
HR (95%CI) 
 
p-value 
 
HR (95% CI) 
 
p-value 
 
LRT χ
2
 p-value 
 
Age (years) 
≤65 25  (18/72) ref.      
>65 26  (7/27) 0.99 (0.41-2.38) 0.99     
Gender 
female 21  (9/43) ref.      
male 29  (16/56) 1.40 (0.62-3.18) 0.42     
Etiology 
alcohol 20  (16/81) ref.      
other 50  (9/18) 3.18 (1.40-7.22) 0.006 4.18 (1.6-10.94) 0.004 7.98 0.005 
Co-morbidities 
absent 15  (7/48) ref.      
present 35  (18/51) 2.67 (1.12-6.40) 0.03 4.48 (1.57-12.8) 0.005 8.84 0.003 
Ascites 
absent 25  (3/12) ref.      
present 25  (22/87) 0.97 (0.29-3.24) 0.96     
AD in previous 
6 months 
absent 21  (12/58) ref.      
present 32  (13/41) 1.53 (0.70-3.35) 0.29     
MELD scorea 
≤21 10  (7/68) ref.      
>21 57  (17/30) 7.46 (3.1-18.1) <0.001 5.27 (2.08-13.3) <0.001 13.65 <0.001 
CRP (mg/L) 
≤30 8  (4/48) ref.      
>30 41  (21/51) 6.03 (2.06-17.6) 0.001 2.08 (0.5-8.53) 0.31 1.11 0.29 
sCD163 (ng/mL) 
≤7000 17  (11/61) ref.      
>7000 42  (14/33) 3.04 (1.38-6.71) 0.006 2.96 (1.27-6.95) 0.012 6.23 0.013 
Leukocyte countb  1.09 (1.03-1.15) 0.004 1.12 (1.04-1.20) 0.003 
 
8.26 
 
0.004 
 
a MELD score was not available in 1 patient, due to missing albumin and creatinine 
level. 
29 
 
b Hazard ratio was calculated for 1G/L increase in leukocyte count 
CI: confidence interval, LRT: likelihood ratio test, χ
2
: Chi-square, ref.: reference 
category, NSSBs: non-selective beta-blockers, PPI: proton-pump inhibitors 
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Figure 1. Serum sCD163 levels in stable outpatients with cirrhosis according to 
the presence of portal hypertension. Median sCD163 levels are not different 
significantly in patients between with or without (A) ascites, (B) prior variceal bleeding or 
esophagal varices*. Lines denote median values, boxes represent 25-75th percentiles 
and whiskers indicate the 5-95th range. P values were calculated by Mann-Whitney U-
test.  
* only patients screened for esophagal varices by esophago-duodenoscopy within 2 
years around the study enrolment were included. 
 
Figure 2. Serum sCD163 levels in patients with acute decompensation event 
according to presence or absence of bacterial infections. Median sCD163 levels 
are significantly higher in patients with infection as compared to those without. Lines 
denote median values, boxes represent 25-75th percentiles and whiskers indicate the 
5-95th range. P values were calculated by Kruskal-Wallis test and Dunn’s post hoc test 
as appropriate. 
 
Figure 3. Kaplan – Meier survival plot of short-term mortality in patients with 
acute decompensation. (A) In patients with bacterial infection, 28-day mortality rate is 
higher in patients with serum sCD163 level > 7000ng/ml, compared to those with lower 
level. (B) In patients without bacterial infection there is no difference in 28-day mortality 
rate according to sCD163 level. 
 
Figure 4. Relationship between the estimated 28-day mortality rate and leukocyte 
count according to MELD score and sCD163 level. Cut off values were >21 for 
MELD and >7000 ng/ml for sCD163 by Youden-index.  
 
